Technology-Driven Precision Medicine Company Variantyx Secures $41.5M In Funding

Feb 14, 2022•over 3 years ago

Amount Raised

$41.5 Million

Framingham

Description

Variantyx, a technology-driven precision medicine company providing advanced genomic testing for the rare genetic disorders, reproductive health, and precision oncology markets, today announced they have secured $41.5M in funding. The series C-2 funding round, led by New Era Capital Partners and includes Peregrine Ventures, Robert Bosch Venture Capital, 20/20 HealthCare Partners, and Pitango HealthTech, will be used to fuel company growth and launch newly developed solutions across all markets, with a focus on precision oncology.

Company Information

Company

Variantyx

Location

Framingham, Massachusetts, United States

About

Variantyx is a technology-driven precision medicine company providing disruptive solutions for the genetic disorders, reproductive health, and precision oncology markets. The proprietary whole genome analysis platforms developed by Variantyx allow clinicians and patients to better understand a person's genetic makeup, leading to unmatched diagnostic capabilities and improved personalized treatment recommendations. For more information, please visit www.variantyx.com. Contact:DeeDee Rudenstein drudenstein@propelsc.com SOURCE Variantyx

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Technology-Driven Precision Medicine Company Variantyx Secures $41.5M In Funding

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information